Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
You can read the abstract of this article at In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide demonstrated superior reductions in HbA1c concentrations, bodyweight, and blood pressure compared to titrated daily insulin glargine in individuals with type 2 diabetes and cardiovascular risk
Sandoz has said it expects the market to take shape in the third quarter of 2026, depending on Health Canada's review process and any additional information requests
As such, its important that weight-loss medication is used as part of a broader approach to healthy weight management, including access to appropriate nutrition, physical activity and behavioural support. Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, said: Expanding the range of effective treatments is important in helping people sustainably reduce caloric intakes within an increasingly obesogenic environment
doi: 10.1038/nm.3361 96 PerkinsMNRothwellNJStockMJStoneTW
